A conjugate meningococcal vaccine (Menactra) was licensed in the U.S. in January 2005 and is recommended for all 11- and 12-year-olds, students entering high school, and college freshmen dormitory ...

The concomitant administration of multiple vaccines at a single clinic visit reduces the number of required visits to healthcare providers and can improve compliance with vaccine recommendations ...

ACIP recommends pentavalent meningococcal vaccine Penmenvy (meningococcal Groups A, B, C, W, and Y vaccine) for individuals 10 through 25 years of age.

The meningococcal conjugate, or MenACWY vaccine (often called by brand names such as Menactra, Menveo, and MenQuadfi) features a vaccine that targets four of the most common types of bacterial ...

Meningococcal disease is a rare but deadly disease caused by the bacterium Neisseria meningitidis. The disease can progress quickly and take the life of a child within 24 hours. Menactra vaccine was ...

The CDC’s ACIP updated guidance on pneumococcal vaccination, recommending a single dose of PCV for all adults aged 50 years and older.

Pentavalent vaccines can reduce the number of injections required to help protect against invasive meningococcal disease – especially disease caused by serogroup B. Their use could improve ...

. The global meningococcal vaccines market size is anticipated to grow nearly 2X, expanding from USD 4.53 Bn in 2025 to USD 9.05 Bn by 2032, recording a CAGR of 10.4% throughout the forecast ...

The ACIP voted that Penmenvy may be used as part of the adolescent meningococcal vaccination schedule as an alternative to separate administration of MenACWY and MenB. The Centers for Disease ...